A molecular model of the F12 biotherapy shows the fold of its polypeptide backbone. Residual T-cell epitopes are mapped onto the structure and colored from white (no epitopes) to dark red (dense overlapping epitopes). The muted red coloring indicates that T-cell epitopes have been broadly silenced in the engineered F12 variant, and this reduced epitope content underlies the molecule’s improved safety and efficacy profile.
The Centers for Disease Control and Prevention (CDC) has prioritized finding effective treatment of methicillin-resistant Staphylococcus aureus (MRSA), one of the most common bacterial pathogens and the single most deadly drug-resistant bacteria in the United States. Now, a new study led by Dartmouth engineering researchers shows promise for an engineered lysin-based antibacterial agent that may enable safe, repeated dosing to treat life-threatening infections by MRSA and other types of S. aureus.
In recent years, lysins—enzymes naturally produced by microbes and associated viruses—have shown potential to treat S. aureus, which can rapidly acquire resistance to other types of antibiotic drugs.
“Lysins are one of the most promising next-generation antibiotics. They kill drug-sensitive and drug-resistant bacteria with equal efficacy, they can potentially suppress new resistance phenotypes, and they also have this laser-like precision,” said Dartmouth engineering professor and corresponding author Karl Griswold.
While there is promise in lysins, development has been slowed due to concerns that they prompt humans’ immune systems to develop antidrug antibodies, which can have negative side effects including life-threatening hypersensitivity reactions.
That’s why the Dartmouth engineering team—which also included researchers in Dartmouth’s computer science department, The Lundquist Institute at Harbor-UCLA Medical Center, Lyticon, and Stealth Biologics—engineered and patented F12, a new lysin-based antibacterial agent. F12 is essentially able to hide from the human immune system (due to T cell epitope deletion), and therefore does not cause the same negative side effects as unmodified, natural lysins.
F12 is the first lysin-based treatment with the potential to be used multiple times on a single patient, making it ideal to treat particularly persistent drug-resistant and drug-sensitive infections. Preclinical studies showed the efficacy of F12 does not diminish with repeated doses, while two other anti-MRSA lysin treatments currently in clinical trials are only designed to be used a single time.
“We have engineered this super potent, super effective anti-MRSA biotherapeutic, and we’ve done it in a way that renders it compatible with and largely invisible to the human immune system. By making it a safer drug, we’ve enabled the possibility of dosing multiple times in order to treat even the most highly refractory infections,” said Griswold.
The team’s paper, “Globally deimmunized lysostaphin evades human immune surveillance and enables highly efficacious repeat dosing,” was published earlier today by Science Advances. The work was the result of two grants from the National Institutes of Health (NIH) totaling $1.7 million.
The paper details the treatment’s positive results in rabbits, mice with partially-humanized immune systems, and studies with extracted human immune cells. Griswold believes the antibacterial agent could be ready for human clinical trials as soon as 2023.
“This is the first report of a translation-ready deimmunized lysin, and F12 has serious, bonafide clinical potential,” said Griswold.
Further studies of F12 will examine synergy with standard-of-care antibacterial chemotherapies. Preliminary results suggest the combinations are extremely potent and suppress drug-resistance phenotypes.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Drug resistant bacteria
- Fact-checking claims about the delta variant, flesh-eating bacteria and moreon July 2, 2021 at 4:30 pm
CLAIM: Data from the U.K.'s public health agency confirms that those who have been vaccinated against COVID-19 are anywhere from two times to six times more likely to die from the delta variant than ...
- The growing threat of drug-resistant, invasive fungion July 1, 2021 at 12:44 pm
Large numbers of COVID-19 hospitalizations and more immunocompromised people in general are fueling a global spread of a different threatening microbe: invasive fungi.Why it matters: These infections ...
- Antibiotic-resistant bacteria found in cattle, but new technology can help with detectionon June 30, 2021 at 10:46 am
Growing resistance to our go-to antibiotics is one of the biggest threats the world faces. As common bacteria like strep and salmonella become resistant to medications, what used to be easily ...
- Molecule Extracted From Chesnut Leaf Neutralizes Drug-Resistant Bacteriaon June 30, 2021 at 9:22 am
Scientists isolated a molecule, extracted from the leaves of the European chestnut tree, with the power to neutralize dangerous, drug-resistant staph bacteria. Frontiers in Pharmacology published the ...
- Molecule Found in Chestnut Leaves Disarms Staph Bacteriaon June 30, 2021 at 1:03 am
The researchers dubbed the molecule Castaneroxy A, after the genus of the European chestnut, Castanea. The use of chestnut leaves in traditional folk remedies in rural Italy inspired the research.
Go deeper with Google Headlines on:
Drug resistant bacteria
Go deeper with Bing News on:
F12 lysin-based antibacterial agent
- Antimicrobial agents and chemotherapyon June 26, 2021 at 5:00 pm
Efficacy of a Cap-Dependent Endonuclease Inhibitor and Neuraminidase Inhibitors against H7N9 Highly Pathogenic Avian Influenza Virus Causing Severe Viral Pneumonia in Cynomolgus Macaques ...
- ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forumon June 17, 2021 at 4:52 am
Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections (BSIs) also known as ...
- ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Developmenton June 17, 2021 at 4:49 am
Dr. Woodnutt has over 30 years of experience leading the discovery and development of innovative therapies ranging from antibiotics to novel protein-based ... and to combat antimicrobial resistance." ...
- Leica M320 F12 ENT Microscope with New Multifocal Lens, High Definition Cameraon June 1, 2021 at 5:00 pm
Leica Microsystems has upgraded its Leica M320 F12 ENT surgical microscope with ... The surface is protected with a permanent antimicrobial coating, AgProtectTM. Patients and healthcare ...
- ContraFect Reports First Quarter 2021 Financial Results and Provides Business Updateon May 14, 2021 at 4:34 am
Exebacase is a recombinantly-produced lysin (cell wall hydrolase ... milestone for direct lytic agents as native lysins are typically unable to penetrate the outer membrane of Gram-negative bacteria.